ASH 2014: AbbVie's venetoclax gets responses in pre-treated AML
This article was originally published in Scrip
Acute myelogenous leukemia (AML) patients enrolled in AbbVie's ongoing Phase II clinical trial for venetoclax (ABT-199) achieved 19% overall response rate, but even with fewer than one-fifth of patients responding, the trial's lead investigator said the results were "promising" in this heavily pre-treated population.
You may also be interested in...
Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Public Company Edition: Moderna leveraged its all-time high stock price to raise $1.34bn on the same day it reported data from a Phase I trial of its COVID-19 vaccine. Several other companies also took advantage of biopharma’s rising value.